Key result
Incubation with recombinant neutral endopeptidase resulted in a much more rapid degradation of radioactively labelled ANP compared to labelled urodilatin.
Why the study?
Does urodilatin resist degradation by recombinant neutral endopeptidase better than ANP?
Does urodilatin resist degradation by recombinant neutral endopeptidase better than ANP?
Urodilatin is more resistant to degradation by neutral endopeptidase than ANP, suggesting potential therapeutic utility in conditions where ANP is ineffective.
No takes yet. Share an insight, caveat, or question.
Urodilatin may resist NEP degradation better than ANP; leaves open therapeutic testing in human cardiorenal disease.
Abassi et al. (1994) studied this question. [125I]-urodilatin vs. [125I]-ANP was evaluated on Degradation rate by pure recombinant NEP (rNEP). Incubation with recombinant neutral endopeptidase resulted in a much more rapid degradation of radioactively labelled ANP compared to labelled urodilatin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: